Introduction
The relationship between genetic engineering and the public has never been a very harmonious one. From the early 1970s onwards, the interaction between recombinant DNA research and society was fraught with tension and conflict. While some perceived genetic engineering as a technology of the future, others saw it as a potential source of disaster. Overhyped promises and exaggerated predictions of the impacts of genetic engineering raised not only hopes, but also suspicion, concerns and anxiety. Within this difficult context, gene therapy occupies a prominent place.
From its early days on, gene therapy advanced a highly optimistic scenario of its future. During the 1990s, the pioneers in the field raised hopes of soon being in a position to cure single-gene disorders, such as cystic fibrosis and severe combined immunodeficiency. 1 These predictions and announcements created strong expectations, but also a broad range of concerns, such as the difficulty in distinguishing between the 'good' and the 'bad' uses of genetic modification, the question of altering human traits not associated with disease, or the problem that many candidates of gene therapy are too young to understand the ramifications of gene therapy treatment. 2 In the meantime, current discourse in gene therapy has become much more cautious and the focus of attention has shifted from genetic disorders to using gene therapy as part of the strategies to confront major health challenges, such as cancer and other diseases. 3 However, as the public reactions to the death of Jesse Geisinger which occurred during a course of gene therapy treatment showed, gene therapy continues to be closely watched and a singular accident can cause far-reaching debate about the legitimacy of gene therapy.
Many scientists consider the suspicions and anxieties around the project of gene therapy as unjustified and farfetched. In fact, there seems to be a widespread feeling in the scientific community that many of the concerns about gene therapy are simply based on misunderstandings and lack of scientific information. In this 'deficit theory' of the public, most difficulties in the interaction between science and the public are derived from the assumption that there is a communication gap between scientists and the public. A large portion of the population in the United States and in Europe, so the argument goes, does not understand the basics of science and thus judges scientific advances based on prejudice, rather than on knowledge. Hence, it is a crucial task of the scientific community to improve the public understanding of science and to have mediators which bring the two worlds of science and the public closer together. 4 
How society sees gene therapy
A closer look at solid and sophisticated social scientific studies on public opinion about biotechnology reveals a nuanced image of the public and its understanding of genetic engineering. For Europe, the latest survey results show that the secular trend of declining optimism about biotechnology continues. However, there is strong evidence that people clearly distinguish between the various applications of biotechnology. Assessments tend to be based on perceptions and considerations of usefulness and moral acceptability. While the public does not see substantial benefits in agricultural biotechnology, strong support for the medical applications of biotechnology, even if they are risky, continues to exist. Also, there is no evidence of a correlation between knowledge about biotechnology and attitudes towards it. Those who are well-informed about biotechnology do not necessarily have positive attitudes towards it. At the same time, lack
Gene Therapy of information about genetic engineering does not simply translate as rejection of it. 5 A similar picture emerges from US surveys, which show that the general attitudes toward biotechnology remain positive. Again, it is not so much the level of knowledge and scientific literacy which seems to determine attitudes toward biotechnology, but considerations of moral acceptability. 6 The evidence from these surveys does not suggest that people could not be better informed about genetic engineering than they are, but it gives good reason to reconsider the 'deficit theory' of the public and its policy implications.
If the public is not that ill-informed as is often suggested, what, then, explains the complicated relationship between gene therapy and society? I suggest that it is less lack of information than lack of trust which is at the root of the problem.
Trust, communication and gene therapy
On a general level, trust is an expectation that other people in a society will generally abide by commonly held social norms, roles and ethical principles. People who have this generalized social trust expect their society to function just as it 'should'. 7 However, today we witness in a variety of social fields from politics to science, an erosion of trust. Until recently politics, science or the educational system could rely on the trust and confidence that people collectively stored in or derived from the social institutions. Yet a number of developments have undermined people's trust in the social institutions. Many failures of classical-modernist government have created a widespread awareness of the ubiquity of the unintended, sometimes negative consequences of largescale rationalized planning, big science and the limits to centralized, hierarchical regulation as the dominant mode of collective problem-solving. Today there is deep unease among citizens about the possibilities of effective and responsible state power. There is also a widespread feeling of radical uncertainty. Scientific information or data are not necessarily trusted. In the wake of countless policy disputes based on endless and delegitimizing cycles, scientific expertise and counter-expertise, science has lost much of its authority. As a result of this, trust, be it in politics or in science, cannot be any longer assumed. Today policy-making activities, such as shaping regulations for gene therapy are not simply about finding solutions for a problem, they are as much about finding formats that generate trust among mutually interdependent actors.
If lack of trust is an important explanation for the often uneasy relationship between the public and gene therapy, the way out of the problem cannot be reduced to the project of 'educating the public'. While initiatives to foster the public understanding of science are important, they need to be well-planned and can only be part of a larger design.
In this context, it must be pointed out that currently not enough is known about todaý s different publics and their specific attitudes towards applications of genome medicine. While not even a small company would dare to market a product without having undertaken previous market research, in many areas of medical biotechnology relatively simple 'theories of the public' guide often large-scale efforts to 'educate the public'. It is hoped that these activities will create the appropriate environment for the further dissemination of the newly emerging medical technologies. A recent evaluation of science communication activities in the United Kingdom revealed that overall targeting, marketing and evaluation of science communication activities tend to be simplistic and under-funded. There seems to be an emphasis on events and activities that interest the provider, but few events are designed with the aim of actively engaging and broadening the audience. Furthermore, the report shows that those who are not interested in science believe that they get about the right amount of science information. Those who are interested in science, want to get more information. The group of people that is already interested in science tends to be the audience of most science communication activities, which as a result, mainly reach those who already have a strong interest in science and, overall, tend to have positive attitudes towards science. 8 Most likely these groups are not the ones which lack trust in science.
Toward a strategy to generate trust in gene therapy
A policy design for improving the relationship between the public and the project of gene therapy should, in a first step, identify some basic points of departure to have a solid foundation for further measures.
First, it will be important to understand that 'the public' is a mythical construction which needs to be thoroughly reconsidered. Today's societies are socially, culturally and politically highly diverse and different subgroups of the population have different attitudes, perceptions and understandings of science. 9 A public talk about genetic enhancement of athletic performance might cause sympathetic interest in a US setting, whereas the same speech could cause angry reactions in Germany. Furthermore, 'publics' are not something steady, but more fluid. Attitudes, needs and preferences have some stability, but they change over time and are influenced by contextual circumstances and experiences. In Europe, for example, attitudes towards genetic testing have become more positive over the last 5 years, probably because the perception of its usefulness has become more widespread. At the same time, attitudes towards agricultural biotechnology deteriorated dramatically, partially due to the BSE scare and a number of ill-cast public relations efforts by companies like Monsanto. Thus, any designs to improve the relationship between gene therapy and the public must take into account the dynamic, varied and multi-faceted character of 'the public'.
If the difficult relationship between the public (or the 'publics') and gene therapy cannot be explained by lack of sufficient information or simple misunderstanding of scientific facts and concepts, science communication can only be part of a strategy to improve public attitudes toward gene therapy. These activities need to be welltargeted, carefully designed and aware of the variety of existing socio-cultural settings to have any impact.
Furthermore, it is important to understand that there cannot be one solution or strategy for the relationship between gene therapy and society. Instead, a flexible and situationally appropriate approach must be generated. At the core of these efforts should be the goal to find new formats to generate trust in gene therapy. These formats should reflect a commitment towards transparency, openness, honesty, fairness and enable a critical interchange between researchers, policy-makers and citizens. Such measures could include activities such as the FDA/NIH Gene Therapy Policy Conferences or a further strengthening of aspects of public review mechanism in human gene transfer research. 10 However, additional steps and initiatives definitely are needed, such as local or national dialogue conferences. These initiatives should be based on the currently available knowledge of public attitudes and concerns about genome medicine.
A range of survey data clearly shows that government officials and industry are not considered to be reliable sources of information about biotechnology. Independent academic scientists, NGOs or patient groups operating in the field of medical biotechnology enjoy high trustworthiness. Also, there seems to exist strong evidence that genome medicine is broadly viewed in the US and in Europe as implying a number of risks for patients and society. However, genome technologies are supported because they are perceived to have substantial benefits. Based on this evidence initiatives to build trust between society and gene therapy which could take on different organizational forms should make a special effort to involve independent academic scientists who are prepared to engage in an honest dialogue with the various segments of the potential communities interested in issues of gene therapy. Such dialogues should not be mainly reassuring maneuvers of celebrating the potential benefits of gene therapy, but discuss openly what is known and what is not known in research, the certainties and the uncertainties of clinical trials, the risks and the benefits of human gene transfer research. 11 Neither should the assumption be made that the public can only take 'good news' about gene therapy, nor should it be Gene Therapy assumed that society is not prepared to take any risks when it comes to genome medicine. If those involved in the public understanding of science do not adopt a 'deficit theory' of the public, but conceptualize the public as a regionally, culturally and socially diverse phenomenon and, basically, a competent partner for interaction, a good foundation has been established for further action to improve the complex relationship between society and gene therapy.
